Skip to main content

Table 3 Relation of demographics, lipid profile, and disease-related data with cholesterol efflux capability in SSc patients and controls

From: HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis

  Cholesterol efflux capacity beta coef. (CI95%), p
  Controls (n = 115) Patients (n = 73)
Age, years − 0.03 (− 0.35 to 0.30), 0.88 − 0.04 (− 0.11 to 0.04), 0.32
Male − 3.34 (− 11.34 to 4.66), 0.41 − 1.67 (− 4.81 to 1.47), 0.29
Body mass index, kg/m2 − 0.18 (− 0.59 to 0.24), 0.41 0.14 (0.00 to 0.28), 0.050
Abdominal circumference, cm − 0.13 (− 0.27 to 0.02), 0.097 0.09 (0.03 to 0.14), 0.002
Systolic blood pressure, mmHg − 0.14 (− 0.27 to 0.00), 0.057 0.01 (− 0.03 to 0.06), 0.57
Diastolic blood pressure, mmHg − 0.02 (− 0.06 to 0.02), 0.39 0.01 (− 0.05 to 0.08), 0.67
Cardiovascular comorbidities
 Smoking 4.05 (− 1.39 to 9.50), 0.14 1.50 (− 0.47 to 3.47), 0.13
 Diabetes 0.81 (− 7.72 to 9.35), 0.85 1.63 (− 0.87 to 4.12), 0.20
 Hypertension − 2.75 (− 7.00 to 1.51), 0.20 0.41 (− 1.25 to 2.07), 0.62
 Statins − 2.73 (− 9.16 to 3.69), 0.40 0.35 (− 1.32 to 2.02), 0.68
Analytical and lipid profiles
 CRP, mg/dl   
 Cholesterol, mg/dl 0.04 (− 0.02 to 0.09), 0.17 0.01 (− 0.01 to 0.03), 0.35
 Triglycerides, mg/dl − 0.02 (− 0.06 to 0.03), 0.43 0.01 (− 0.01 to 0.02), 0.36
 HDL cholesterol, mg/dl 0.08 (− 0.03 to 0.20), 0.16 − 0.00 (− 0.07 to 0.07), 0.97
 LDL cholesterol, mg/dl 0.02 (− 0.04 to 0.08), 0.43 0.01 (− 0.01 to 0.03), 0.19
 LDL:HDL cholesterol ratio − 0.31 (− 2.78 to 2.17), 0.81 0.11 (− 0.42 to 0.64), 0.69
 Non-HDL cholesterol, mg/dl 0.01 (− 0.04 to 0.07), 0.66 0.01 (− 0.01 to 0.03), 0.37
 Lipoprotein A, mg/dl 0.04 (− 0.02 to 0.11), 0.16 0.01 (− 0.01 to 0.02), 0.41
 Apolipoprotein A1, mg/dl 0.03 (− 0.03 to 0.09), 0.33 0.01 (− 0.02 to 0.03), 0.62
 Apolipoprotein B, mg/dl − 0.01 (− 0.10 to 0.09), 0.91 0.01 (− 0.02 to 0.04), 0.58
 Apo B:Apo A ratio − 5.19 (− 18.11 to 7.73), 0.43 − 0.39 (− 3.34 to 2.56), 0.79
 Atherogenic index − 0.52 (− 2.63 to 1.60), 0.63 0.01 (− 0.50 to 0.52), 0.97
SS- and treatment-related data
log Disease duration, years   − 0.51 (− 1.47 to 0.45), 0.29
 Modified Rodnan skin score, units   − 0.19 (− 0.34 to − 0.04), 0.014
 Raynaud phenomenon   − 0.54 (− 2.89 to 1.80), 0.64
 Digital ulcers   − 2.50 (− 4.99 to 0.01), 0.049
 Calcinosis   − 0.53 (− 3.25 to 2.18), 0.70
 Arthritis   0.28 (− 2.26 to 1.71), 0.78
 Gastric reflux   0.87 (− 0.78 to 2.53), 0.30
 Pathological esophageal manometry   0.15 (− 1.78 to 2.08), 0.88
 Interstitial lung disease   − 1.34 (− 3.24 to 0.55), 0.16
 Pulmonary hypertension   − 1.14 (− 3.15 to 0.86), 0.26
 Anti-centromere antibody positivity   − 0.34 (− 2.08 to 1.40), 0.70
 Anti-Scl70 antibody positivity   1.80 (− 0.49 to 4.09), 0.12
 Current prednisone   − 0.69 (− 2.67 to 1.28), 0.49
log Prednisone   − 2.22 (− 6.83 to 2.40), 0.32
 DMARDs   − 0-00 (− 2.33 to 2.33), 0.99
Azathioprine   − 0.33 (− 3.95 to 3.07), 0.80
Methotrexate, n (%)   0.96 (−3.93 to 5.86), 0.70
Hydroxychloroquine, n (%)   − 0.85 (− 5.74 to 4.05), 0.73
  1. ANA antinuclear antibodies; BMI body mass index; CRP C-reactive protein; DMARD disease-modifying anti-rheumatic drug; HDL high-density lipoprotein; LDL low-density lipoprotein